Pharmaceutical Giants: GLP-1 Weight Loss Dominance vs Diversified Healthcare
LLY vs JNJ: Head-to-Head Comparison
Comparing quantitative economic moats, Forward P/E multiples, balance sheet liquidity, and institutional 13F whale conviction.
👑 Higher Moat Score
LLY
LLY 🇺🇸
Eli Lilly and Company
$1,115.70
-0.65%
MOAT SCORE
⚡ 88.0/100
VS
📊 Quantitative Fundamental Matchup
| Fundamental Metric | LLY (Eli Lilly and Company) | JNJ (Johnson & Johnson) | Advantage |
|---|---|---|---|
| Moat Score™ (0-100) | ⚡ 88.0 | ⚡ 87.0 | LLY (+1.0 pts) |
| Market Capitalization | $994.9B | $640.0B | - |
| Forward P/E Ratio | 30.4x | 24.0x | JNJ (Cheaper Multiple) |
| Trailing P/E Ratio | 37.5x | 30.8x | - |
| Gross Profit Margin | 83.4% | 68.1% | LLY (Higher Pricing Power) |
| YoY Revenue Growth | +47.7% | +6.6% | LLY |
| Free Cash Flow | $11.1B | $16.9B | - |
| Superinvestor 13F Backing | None Tracked | None Tracked | - |
🏆 The MoatPicks Verdict: LLY Wins on Fundamentals
Based on our 12-point quantitative audit, LLY (Eli Lilly and Company) achieves an overall Moat Score of 88.0/100 compared to 87.0/100 for JNJ. LLY demonstrates superior capital allocation efficiency, wider gross margins, and stronger defensive economic moat characteristics in the Pharmaceutical Giants sector.
Find All 100+ Top-Ranked Moat Compounders
Get real-time 3-hour price updates, 13F whale transaction alerts, and complete 12-point fundamental breakdowns.
Unlock MoatPicks PRO →